Content about Formoterol

March 25, 2014

Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.

PITTSBURGH — Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution. Mylan previously sued Teva alleging that Teva's abbreviated new drug application for this product infringed four Mylan patents covering Perforomist.  

The court's decision prevents Teva's ANDA, which has yet to receive a tentative approval from the Food and Drug Administration. 

July 8, 2013

A chronic obstructive pulmonary disease and asthma drug made by Sunovion infringes Mylan's patents on a similar drug, a federal judge has ruled, Mylan said.

PITTSBURGH – A chronic obstructive pulmonary disease and asthma drug made by Sunovion infringes Mylan's patents on a similar drug, a federal judge has ruled, Mylan said Monday.

The U.S. District Court for the Southern District of New York ruled that Sunovion's Brovana (arformoterol tartrate) infringes five patents related to Perforomist (formoterol fumarate), made by Mylan Specialty, the drug maker's branded products division.

June 10, 2013

Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

LONDON — Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

The company announced that it would buy Redwood City, Calif.-based Pearl Therapeutics, which has an inhaled drug for chronic obstructive pulmonary disease, called PT003 (formoterol fumarate; glycopyrrolate), in late-stage clinical development.

May 21, 2013

A federal appellate court has ruled in favor of Mylan in a case involving a drug for chronic obstructive pulmonary disease, the drug maker said.

PITTSBURGH — A federal appellate court has ruled in favor of Mylan in a case involving a drug for chronic obstructive pulmonary disease, the drug maker said Tuesday.

Mylan said that the Court of Appeals for the Federal Circuit had reversed a lower court's decision invalidating five patents held by subsidiary Mylan Specialty for Perforomist (formoterol fumarate) in a case filed in 2007 against Dainippon Sumitomo Pharma subsidiary Sunovion Pharmaceuticals over the drug Brovana (arformoterol tartrate).

November 14, 2010

Most patients with mild persistent asthma overuse a drug combination despite an apparent lack of...

PHOENIX — Most patients with mild persistent asthma overuse a drug combination despite an apparent lack of added medical benefit, according to a new study by pharmacy benefit manager Medco.

June 23, 2010

The Food and Drug Administration has approved a new drug by Merck for treating asthma...

June 6, 2010

The class of drugs known as long-acting beta agonists can provide many benefits to patients...

May 10, 2010

Nearly one-third of patients with asthma are taking their medications in a way that puts...

FRANKLIN LAKES, N.J. Nearly one-third of patients with asthma are taking their medications in a way that puts them at risk for worsening symptoms and death, according to a new study by pharmacy benefit manager Medco Health Solutions.

February 24, 2010

Mylan had profits of $93.5 million in 2009, the generic drug maker announced Thursday in...

February 18, 2010

British drug maker GlaxoSmithKline issued a response to new labeling requirements proposed by the Food...

February 17, 2010

Drugs belonging to the class called long-acting beta agonists should never be used alone for...